Migraine Medication Battle: Eli Lilly Prevails in Patent Infringement Case Against Teva
Portfolio Pulse from Vandana Singh
A federal judge has overturned a $176.5 million jury verdict against Eli Lilly (LLY) in a patent infringement case favoring Teva Pharmaceutical (TEVA). The case revolved around Lilly's migraine drug, Emgality, allegedly infringing upon three patents related to Teva's rival drug, Ajovy. The judge ruled that the Teva patents were invalid. Eli Lilly generated over $650 million in revenue from Emgality in FY22, while Teva earned $377 million from Ajovy.
September 27, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The overturning of the verdict is a positive development for Eli Lilly as it removes a significant financial liability and allows the company to continue selling its migraine drug, Emgality.
The judge's decision removes a significant financial liability for Eli Lilly and allows the company to continue selling its migraine drug, Emgality, without fear of infringing on Teva's patents. This could potentially lead to increased revenues for Eli Lilly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
The ruling is a setback for Teva Pharmaceutical as it invalidates their patents and removes the awarded damages of $176.5 million. This could potentially impact the revenues from their migraine drug, Ajovy.
The judge's decision invalidates Teva's patents and overturns the awarded damages of $176.5 million. This could potentially lead to decreased revenues for Teva from their migraine drug, Ajovy, as it allows Eli Lilly to continue selling their competing drug, Emgality.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100